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Abstract
Background: This case study describes how a public-private partnership initiated to develop a new anti-malarial
combination, ASAQ Winthrop, has evolved over time to address issues posed by its effective deployment in the field.
Case description: In 2002, DNDi created the FACT project to develop two fixed-dose combinations, artesunate-
amodiaquine and artesunate-mefloquine, to meet the WHO anti-malarial treatment recommendations and
international regulatory agencies approval standards. In 2002, Sanofi-aventis had started a development
programme for a fixed-dose combination of artesunate and amodiaquine, to replace its co-blister combination.
DNDi and sanofi-aventis joined forces in 2004, with the objective of developing within the shortest possible time
frame a non-patented, affordable and easy to use fixed-dose combination of artesunate and amodiaquine adapted
to the needs of patients, in particular, those of children. The partners developed Coarsucam
®/Artesunate
Amodiaquine Winthrop
® ("ASAQ Winthrop”) which was prequalified by the WHO in 2008. Additional partnerships
have since been established by DNDi and sanofi-aventis to ensure: 1) the adoption of this new medicine by
malaria-endemic countries, 2) its appropriate usage through a broad range of information tools, and 3) the
monitoring of its safety and efficacy in the field through an innovative Risk Management Plan.
Discussion and evaluation: The partnership between DNDi and sanofi-aventis has enabled the development and
pre-qualification of ASAQ Winthrop in a short timeframe. As a result of the multiple collaborations established by
the two partners, as of late 2010, ASAQ Winthrop was registered in 30 sub-Saharan African countries and in India,
with over 80 million treatments distributed in 21 countries. To date, 10 clinical studies, involving 3432 patients with
ASAQ Winthrop were completed to document efficacy and safety issues identified in the Risk Management Plan.
Conclusions: The speed at which ASAQ Winthrop was adopted in the field shows that this drug fits the needs of
patients and health authorities. It also demonstrates the power of partnerships that combine different sets of strengths
and skills, and that evolve to include additional actors to meet new global health challenges for poverty-related diseases.
Background
Due to the high efficacy of artesunate-based combina-
tion therapy (ACT) in the treatment of uncomplicated
malaria in Africa and Asia, a technical consultation
organized by the WHO in 2001 recommended their use
to provide effective treatment against malaria and to
slow down the spread of drug resistance. In 2006, WHO
further stated its preference for ACT in fixed-dose com-
binations to overcome the issues related with non-fixed
dose options [1]. The fixed dose combination had been
identified by experts assembled in 2003 by the WHO as
highly desirable in terms of adherence and ease of treat-
ment, containment of resistance, reduction of diversions
and possibly reduction of costs [2].
A partnership was initiated in 2004 between the Drugs
for Neglected Diseases initiative (DNDi) and sanofi-
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artesunate and amodiaquine, one of the forms of ACT
recommended by the WHO, which at that time only
existed as a non-fixed combination of the two drugs.
This case study aims at retracing the main features of
this partnership, and describes how it was progressively
enlarged to include new partners to maximize the
launch and distribution of the new medicine. The les-
sons from this experience may help in the development
of other need-driven drugs.
Case description
The FACT project: 2002-2004
In 2002, under the auspices of the DNDi Working
Group, which led to the creation of the DNDi founda-
tion in 2003, the Fixed-Dose Artesunate-based Combi-
nation Therapies (FACT) Project was initiated. Its aim
was to develop two fixed-dose combinations, namely
artesunate-amodiaquine and artesunate-mefloquine, in
the shortest possible timeframe to meet the WHO
treatment recommendations and international quality
standards. The FACT project consisted of DNDi,
Farmanguinhos/Fiocruz (Brazil), Tropival of the Bor-
deaux II Victor-Segalen University (France), Oxford
University (UK), Universiti Sains (Malaysia), Mahidol
University (Thailand), the Special Programme for
Research and Training in Tropical Diseases WHO/
TDR (Switzerland), and the Centre National de
Recherche et de Formation sur le Paludisme (Burkina
Faso). In line with DNDi’s mission of collaboration
based on relative strengths, the FACT project capita-
l i z e do nt h es k i l l sa n dk n o w - h o wo fab r o a dr a n g eo f
partners in both developing and developed countries.
Initially, the FACT project was financially supported
by the European Union (INCO-Dev programme) and
Médecins Sans Frontières, then by government agen-
cies from France, the Netherlands, Spain and the UK.
At the end of 2004, the formulation of the “bilayer”
tablet had been developed with good stability charac-
teristics and a packaging that guaranteed stability in
tropical field conditions [3,4]. A first scale-up to pre-
industrial stage had occurred at Rottendorf Pharma
(Germany). Clinical studies were ongoing in healthy
volunteers in Malaysia and in patients in a comparative
study in Burkina Faso [5]
Meanwhile, in 2004, sanofi-aventis had registered and
launched a co-blistered, non-fixed form of artesunate
and amodiaquine (Arsucam
®) in sub-Saharan Africa.
Recognizing the advantages of fixed-dose combinations
to improve patient compliance, dosing accuracy and
avoiding the risks related with monotherapy, the com-
pany had also initiated, in 2002, a programme to
develop a fixed-dose combination of artesunate and
amodiaquine.
The sanofi-aventis - DNDi development partnership:
2004-2008
In December 2004, DNDi and sanofi-aventis decided to
join forces to form a public-private partnership with the
objective of developing a non-patented fixed-dose com-
bination of artesunate and amodiaquine that would be
made available at prices lower than those available at
the time, i.e. less than US$1 for an adult treatment and
less than US$0.50 for a child’s treatment in the non-
profit public sector. Sanofi-aventis did not seek any
patent protection. This decision was made to be consis-
tent with DNDi’s intellectual property policy to develop
drugs as public goods when possible, and with both
partners’ determination to make the new medicine
widely available to those patients in greatest need.
Sanofi-aventis agreed to pay DNDi 3% of the net private
sector turnover over a period of seven years. DNDi
decided to use this payment to support the Risk Man-
agement Plan, which is described later in this paper.
DNDi’s key contribution at the initial stage of the
partnership was brought by the University Victor-Sega-
len of Bordeaux and then by Ellipse Pharma (France),
which developed the “bi-layer” formulation with the
objective of keeping separated the artesunate and the
amodiaquine components, and defined the key features
of the manufacturing process of the fixed-dose combina-
tion. The process allowed for a reduction in the size and
number of tablets, as well product stability in tropical
climates [3,6].
Once collaboration was started, regular joint projects
teams between sanofi-aventis and DNDi enabled making
the most of each partner’s skills and resources, and a steer-
ing committee provided arbitrage in case of disagreement.
Project teams composition evolved over time as required
by the various steps of the development (regulatory, pre-
clinical, clinical, industrial, etc.). Meetings between the
two parties were jointly managed by one representative of
each partner. The roles and responsibilities of each part-
ner, and, therefore, the rules for decision-making, were
laid out early on. DNDi was responsible for the actual for-
mulation of ASAQ Winthrop, early Phase I data, as well as
for one pivotal comparative study. Sanofi-aventis was in
charge of the manufacturing process at industrial scale,
managing the second pivotal clinical study, building the
registration file, ensuring registration in endemic coun-
tries, obtaining WHO pre-qualification and launch and
marketing of the new drug. Decisions which could not be
reached by consensus between the two parties were dis-
cussed at steering committee meetings which occurred
approximately four times a year. When consensus could
still not be reached, the final decision was made by the
party responsible for carrying out the task under consid-
eration. Collaborative work between the two partners led
to the following outcomes:
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The development of the ASAQ Winthrop tablets
strengths was focused towards optimizing safe and effec-
tive drug levels across all age groups, with a specific
emphasis on the needs of children who are the first vic-
tims of malaria. The formulation of ASAQ Winthrop
enables the drug to be dissolved in water, making it
easier to administer to infants and small children. In
most endemic countries, dosing recommendations based
on age are simpler to use in the field than those based
on bodyweight. DNDi was of the opinion that the age-
based dosing was more practical in developing countries.
Sanofi-aventis, however, was in favour of developing a
weight-based formulation in keeping with major regula-
tory agencies regulations. Both partners came to consen-
sus thanks to an innovative body of work that modeled
actual weight-for-age data from malaria endemic African
countries [7]. This dataset, referred to as the malaria
weighted anthropometric reference (MWAR) dataset,
allowed the design of practical weight and age-based
regimens to maximize the proportions of patients
receiving appropriate drug doses, while avoiding the risk
of over- and under-dosing artesunate and amodiaquine.
The strategy of dose accuracy provided a definition of
acceptable dosing ranges for both drugs. The dosing
ranges for artesunate and amodiaquine were:
- artesunate: 2 to 10 mg/kg (5 fold), reflecting its tol-
erability and, therefore, wide
- therapeutic index.
- amodiaquine: 7.5 to 15 mg/kg (2 fold). There was
less flexibility with amodiaquine, therefore, amodiaquine
determined the final dosing and age categories.
In addition, two conventions were adopted:
- select age groups with an approximate doubling in
median bodyweight, and
- double the drug dose per age category.
These conventions led to selecting 4 dosage forms
based on age and weight ranges, for infants (4.5 to 8 kg,
2 to 11 months), toddlers (9-17 kg, 1 to 5 years), chil-
dren (18-35 kg, 6 to 13 years) and adults (> 36 kg, 14
years and above). Figure 1 shows the dosing regimen of
ASAQ Winthrop, compared with that of the non-fixed
combination.
Preparation of the registration dossier
Between 2004 and 2007, a joint project team was set up
between sanofi-aventis and DNDi to cover all tasks
required to license ASAQ Winthrop: industrial pharma-
ceutical development (i.e. development of processes
required to reach production on an industrial scale at
the Maphar-sanofi-aventis plant in Casablanca, Mor-
occo); pre-clinical pharmaco-toxicology studies to docu-
ment the safety profile of artesunate plus amodiaquine
in animals; clinical (from Phase I studies to document
the drug’s pharmacokinetics, to Phase III well-controlled
clinical studies to document its safety and efficacy in
malaria patients); regulatory (preparation of registration
files for Morocco, sub-Saharan malaria endemic coun-
tries and WHO pre-qualification process), as well as
marketing and medical activities to prepare the drug’s
launch and marketing in endemic countries and design
post-launch clinical studies to monitor its safety and
efficacy in the field.
The registration dossier included clinical data on 1,003
patients treated with ASAQ Winthrop from two rando-
mized controlled studies: one managed by DNDi in Bur-
kina Faso comparing ASAQ Winthrop to a non-fixed
combination of artesunate and amodiaquine [5], and
another study managed by sanofi-aventis, set up in
Senegal, Mali, Cameroon and Madagascar, comparing
ASAQ Winthrop to artemether-lumefantrine [8]. In
addition, clinical data on over 6,000 patients treated
with non-fixed combination of artesunate and amodia-
quine were provided.
Registration of Coarsucam/ASAQ Winthrop
Many discussions were held over the best way to regis-
ter ASAQ Winthrop to make it available as quickly as
possible in endemic countries, while demonstrating its
adherence to high-quality standards. It was decided to
seek initial registration from Morocco, the country
where the drug is manufactured, to enable registration
in endemic countries, but to also apply for WHO pre-
qualification as further evidence of ASAQ Winthrop’s
quality standards, and to enable purchasing by interna-
tional agencies, The Casablanca production plant was
chosen in line with sanofi-aventis’ commitment to
develop its existing industrial assets in developing and
emerging countries. A major financial investment was
made to ensure appropriate production capacity level, as
well as adherence of the plant to Good Manufacturing
Practice standards. To allow for differential pricing
between the public and private markets, two brand
names were selected: Coarsucam
®, for private markets
(1 blister per box), and Artesunate Amodiaquine Win-
throp
® for public markets (25 blisters per box). Win-
throp is the name of sanofi-aventis generic range of
medicines. The shortened name “ASAQ Winthrop” in
this article refers to both brand names and is used to
highlight the fact that this product is a specific fixed-
dose combination of artesunate and amodiaquine. The
registration dossier was submitted in December 2005
and approval was granted in Morocco on February 1,
2007, making ASAQ Winthrop the first new anti-malar-
ial treatment developed and delivered by a public-pri-
vate partnership [6]. Following this, registration
applications were submitted in 30 malaria-endemic Afri-
can countries and approval were obtained between
November 2006 (in Benin) and December 2010. The
decisive step which enabled rapid exportation to other
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Morocco, the country of manufacturing of the medicine,
Sanofi-aventis submitted a dossier to the WHO pre-quali-
fication process in February 2007. Following review of the
submitted data, and two Good Manufacturing Practice
inspections of the manufacturing plant, the WHO granted
a “pre-qualified” status in October 2008. This status
opened the door to purchases of ASAQ Winthrop by
malaria-endemic countries funded by international organi-
zations resulting in 6 million treatments in 2008 to 25 mil-
lion in 2009 and over 45 million in 2010. In keeping with
the principles of sanofi-aventis’ Access to Medicines
approach, ASAQ Winthrop is made available through a
tiered-pricing policy, that includes “no profit-no loss”
prices for ASAQ Winthrop in the public sector (govern-
ments, non-profit NGOs, etc.), while the same drug is sold
in the private sector under a different brand name (Coar-
sucam
®), at market prices that include profit margins. Spe-
cifically, ASAQ Winthrop is available in the public sector
at prices below $1 for adults and $0.50 for children, while
Coarsucam
® is sold for approximately $2-$3 to wholesa-
lers for the private markets. The profit margins made
though sales in the private sector ensure that the mechan-
isms that enable very low “no profit-no loss” prices in the
public sector can be sustained over the long-term.
The ASAQ Winthrop Risk Management Plan
Early in their collaboration, sanofi-aventis and DNDi
wanted to ensure that appropriate post-marketing data
was available as quickly as possible on ASAQ Winthrop
safety and effectiveness in the field. This was deemed
necessary because of the relatively poor image of amo-
diaquine safety, in spite of its re-installment in the
1990s as a safe and effective drug for the treatment of
malaria [9]. Also, because multiple associations of arte-
sunate and amodiaquine, with different drugs ratios and
quality standards, have been used in the past, it was felt
crucial to document the specific safety and efficacy pro-
file of ASAQ Winthrop. Further no pharmacovigilance
data could be expected from industrialized countries
and existing pharmacovigilance systems in sub-Saharan
Africa were not sufficiently operational to reliably docu-
ment the safety profile of this drug. The “ASAQ Win-
throp deployment monitoring plan” was, therefore,
designed to provide quality efficacy and safety data
through a variety of proactive studies, each providing
different types of data. These studies range from rando-
mized, comparative, clinical trials in limited number of
patients treated under well-controlled conditions (who
would be extensively followed-up during each of their
treated malaria episodes) to large-scale studies assessing
Fixed-dose ASAQ
artesunate/amodiaquine
Co-blistered, non-fixed AS+AQ
artesunate + amodiaquine
Infants
< 8 kg, 2 to 11 months 
1 tablet
(AS 25mg / AQ 67.5mg) 
½ tablet AS (50 mg)
½ tablet AQ (135 mg) 
Young children
8-17 kg, 1 to 5 years 
1 tablet
(AS 50mg / AQ 135 mg) 
1 tablet AS (50 mg)
1 tablet AQ (135 mg) 
Children
17-35 kg, 6 to 13 years 
1 tablet
(AS 100 mg / AQ  270 mg) 
2 tablets AS (50 mg)
2 tablets AQ (135 mg) 
Adults
> 35 kg, > 14 years 
2 tablets
(AS 100 mg / AQ 270 mg) 
4 tablets AS (50 mg)
4 tablets AQ (135 mg) 
Figure 1 ASAQ Winthrop and non-fixed combination dosing regimens. Simplified dosing regimen with fixed-dose ASAQ. The bi-layer
formulation allows for AS and AQ to be taken together, in correct proportions, with fewer tablets as compared with the co-blistered non-fixed
dose options.
Bompart et al. Malaria Journal 2011, 10:143
http://www.malariajournal.com/content/10/1/143
Page 4 of 9the drug’ss a f e t yi n“real-life” conditions. These studies
are performed in several countries of West and East
Africa, with various malaria transmission patterns, to
provide a comprehensive picture on the safety and effec-
tiveness of ASAQ Winthrop. This programme includes
the following key studies, which are at various stages of
completion:
- Several randomized controlled studies in sub-
Saharan African countries that provide safety and
efficacy data on ASAQ Winthrop, compared with
other forms of ACT, usually in the treatment of sin-
gle malaria episodes in patients with documented
malaria.
- Two cohort studies in Senegal and in Uganda: in
each study, cohorts of 200 patients were randomly
assigned to receive either ASAQ Winthrop or arte-
mether-lumefantrine for each malaria attack occur-
ring during the two-year study period. The Uganda
study focuses on children less than five years of age.
The Senegal study includes both adults and children.
- A Phase IV field programme to assess ASAQ Win-
throp “real life” safety and effectiveness over two
years in a Côte d’Ivoire health district that uses
ASAQ Winthrop as first-line treatment, through two
approaches. First, an active monitoring of clinical tol-
erability and compliance for all malaria patients
attending district health centres for treatment, per-
formed by community health care workers who visit
treated patients at home to collect information. In
this study, patients diagnosed with malaria are pre-
scribed ASAQ Winthrop to take at home under non-
supervised conditions as is standard medical practice
currently in Côte d’Ivoire. Blood smears are collected
to enable post-treatment laboratory diagnosis of
malaria, to identify which patients definitely had
malaria. This approach will enable getting a “real-life”
view of the drug’s safety and efficacy in patients trea-
ted after clinical diagnosis as frequently happens in
Africa, and to assess possible differences between
patients with and without biologically-proven malaria.
T h eW o r l dM a l a r i aR e p o r t2 0 0 9[ 1 0 ]a n dt h eG u i d e -
lines for the Treatment of Malaria 2010 of the WHO
[11] recommend prompt parasitological confirmation
by microscopy or with Rapid Diagnostic Tests for all
patients with suspected malaria before treatment is
started. When Côte d’Ivoire implements these recom-
mendations, the study procedures will be changed
accordingly. The second part of the programme con-
sists in a clinical safety and efficacy study, at baseline
and after two to three years of implementation, to
assess the evolution of malaria parasites susceptibility
to the artesunate-amodiaquine combination under
well-controlled conditions.
As more data on ASAQ Winthrop, generated through
studies managed by either one of the two partners or by
other institutions become available, they will be pooled
into a common database and analysed by an academic
investigation team to provide comprehensive informa-
tion on the drug’s efficacy and safety.
The WHO Department of Medicines Policy and Stan-
dards expressed a strong interest in this programme,
and requested a formalized Risk Management Plan
(RMP). This was done in 2009, and a series of docu-
ments was submitted following the format required by
European Medicines Agency for RMP. Table 1 shows
the list of risks and missing information that will be
documented through the RMP. This is the first RMP
ever submitted to the WHO and is based almost exclu-
sively on data collected in Africa. It is expected that the
experience drawn from this initiative will help design
RMPs for future new anti-malarials that will be
launched in developing countries with relatively limited
sets of safety and efficacy data.
In 2009, the Medicines for Malaria Venture (MMV)
joined the sanofi-aventis/DNDi partnership to set up the
Côte d’Ivoire field programme, the most ambitious com-
ponent of the RMP, and is funding most of the costs
thereof. This collaboration was seen by MMV as a way
to develop and test methodologies that could be relevant
to design RMP for future anti-malarials.
Partnering with malaria-endemic countries
The partnership that led to the development and regis-
tration of ASAQ Winthrop had to evolve to ensure the
new drug’s successful launch and adoption by endemic
countries. First among the many partners needed at this
Table 1 ASAQ Winthrop Risk Management Plan: issues to
be documented
1. Identified risks: to be minimized with specific information
￿ Intake during first trimester of pregnancy
￿ Allergy
2. Potential risks: to be quantified in large-scale studies
￿ Hepatotoxicity
￿ Neutropenia/agranulocytosis
￿ Somnolence
￿ Audiometric dysfunction
￿ Extra-pyramidal symptoms
￿ Decreased efficacy (parasite resistance)
3. Missing information: to be documented in new studies
￿ Safety of repeated administrations
￿ Specific populations (HIV/AIDS patients...)
￿ Second and third trimester of pregnancy
￿ Safety profile in non parasitaemic patients
￿ Drug interactions & Interactions with traditional drugs and
remedies
￿ Efficacy in species other than P. falciparum
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Malaria Control Programmes (NMCP) that are charged
with the design and implementation of national action
plans to control malaria. In working to facilitate the
implementation and availability of ASAQ Winthrop,
both sanofi-aventis and DNDi have engaged in colla-
borations with a number of partners, including experts,
national malaria programmes, WHO and other interna-
tional organizations, research institutes, funding agen-
cies, and NGOs. DNDi has, for instance, coordinated a
clinical study with its founding partner, the Indian
Council of Medical Research, to facilitate the adoption
of a new anti-malarial policy in India; this study allowed
registration of ASAQ Winthrop in India. DNDi has also
convened an independent panel of experts, the FACT
Implementation Advisory Group, to provide indepen-
dent advice and critical guidance about issues related to
implementation and rational use of ASAQ Winthrop,
ensuring equitable access.
Information and educational tools
Sanofi-aventis has focused its efforts on supporting the
introduction of the new treatment in public health sys-
tems through a series of information tools to assist with
t h ec h a n g ei np r e s c r i p t i o na n dd i s p e n s i n gh a b i t s .I n
partnership with African NMCP and malaria experts, a
variety of information and educational tools were
designed, not only about the rationale and instructions
on how to use a fixed-dose ACT, but more broadly
about the comprehensive management of the disease,
that includes malaria prevention, diagnosis and treat-
ment. Specific supports are designed for each “constitu-
ency” involved in the fight against malaria, such as
textbooks, slide kits, CDs, educational flipcharts, games,
etc. Information for physicians was focused on malaria
diagnosis and treatment, while those aimed at commu-
nities focused primarily on malaria prevention. These
tools are non-promotional and aim at providing the
most comprehensive and up-to-date information in a
way that is adapted to everyone’s role.
Two of these tools deserve highlighting since they
illustrate how widely different techniques can be used to
convey overall similar messages to different audiences.
Firstly, a “train the trainers” module is proposed to
update countries’ NMCP “senior trainers” on malaria
management. These persons will then be responsible for
cascading the information through the national public
system networks so that best practices are widely used.
A comprehensive training module on malaria diagnosis,
treatment and prevention is delivered by African univer-
sity professors through a three-day workshop organized
with approximately 15 NMCP senior trainers. In addi-
tion to the technical training provided by these experts,
a day is spent with a communication specialist to
improve the educational techniques and teaching skills
of the trainers. Together with supporting materials pro-
v i d e da tt h ee n do ft h et r a i n i n gs e s s i o n ,t h eN M C P
senior trainers are thus better equipped to organize
effective training sessions for their colleagues in the
field.
Another initiative called “Schoolchildren against
Malaria” was designed, aimed at young children approxi-
mately 10 years of age. In this programme, schoolchil-
dren are taught about the basics of malaria, with a focus
on preventative measures at the community level, and
are asked by their teachers to design a theatre play on
this theme.
To create some emulation, a competition is organized
among schools, and the final contest for the best play is
organized as a festive event. Through this approach,
children not only learn about malaria but that they will
also act as information relays for their families and
friends. Between 2008 and 2010, a total of approxi-
mately 200,000 children were involved in this initiative
in Côte d’Ivoire, Ghana and Burkina Faso. This
approach, which builds on the African tradition of oral
culture and theatre, will be expanded to additional
countries in the coming years. Educational tools offered
to countries and NGOs that want to introduce ASAQ
Winthrop are not protected by patents or copyrights so
that they can be used, copied and adapted as broadly as
needed, according to each country’s needs and priorities.
Expanding global partnerships
As is the case for HIV/AIDS and tuberculosis, most of
the malaria drugs made available in public health sys-
tems are bought through international agencies (such as
the Global Fund to fight AIDS, tuberculosis and malaria,
the UNICEF, the President’s Malaria Initiative, etc).
With the advent of the Affordable Medicines Facility-
malaria (AMFm) initiative, major adaptations to the
packaging of eligible medicines are requested by the
funders, to enable, on a country-by-country basis, the
identification of drugs purchased through this facility
[12]. Although one could see interfaces between pur-
chasing agencies and pharmaceutical firms as merely
commercial relationships, information exchanges are so
intense between providers and purchasers that they
often times develop into true partnerships that ensure
the quality, availability and affordability of malaria drugs
to patients.
Discussion and evaluation
This paper intends to illustrate how a two-sided product
development partnership initiated to develop a new
anti-malarial drug has evolved to include additional
partners to address the challenges posed by the launch
of this new drug, its effectivei n t r o d u c t i o ni nn a t i o n a l
programmes, and the need to ensure a steady supply.
What lessons can be drawn from this experience? In
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ASAQ Winthrop, their partnership was perceived as an
unlikely marriage. Nevertheless, one of the world’sl a r -
gest pharmaceutical companies and a not-for-profit
R&D organization successfully brought their respective
strengths together in order to respond to an urgent pub-
lic health need. Through their efforts, the organizations
managed to provide patients with a new anti-malarial
and prove that public and private organizations can suc-
cessfully work together to achieve a common objective.
A successful partnership requires a common desire,
complementary knowledge, and shared responsibilities.
The ASAQ Winthrop partnership between sanofi-aven-
tis and DNDi possessed all of these attributes. ASAQ
Winthrop represents a good example of needs-driven
innovation. While it does not represent an innovative
new molecule developed from the benchtop (which
often requires decades of development and a small
chance of success), it represents a very significant inno-
vation for patients in resource-poor settings. In a disease
where drug resistance represents a major problem, a
fixed-dose combination with a simple dosing regimen
provides a clear improvement over non-fixed combina-
tion of the two separate drugs. The fixed-dose combina-
tion ensures that patients take both drugs
simultaneously and in the correct proportions. The
additional advantage of tablets that can be dissolved in
water was specifically developed for children and it
spared the need to develop a distinct pediatric formula-
tion, which would have required additional time and
funds.
The availability of a new medicine does not imply
access in the field. As such, the partnership made two
bold commitments. First, the product would receive no
patent protection. Second, the partners set a target price
of one 1 USD per treatment for adults and 0.5 USD
cents for children. Before ASAQ Winthrop’si n t r o d u c -
tion to the marketplace, the price for most ACTs in
public markets was approximately 2.50 USD for an
adult treatment. After ASAQ Winthrop’s introduction,
the global reference price for ACTs on public markets
decreased to approximately 1 USD.
Clearly, two organizations with different raisons d’être
will not always agree and will have different views and
approaches towards achieving a common goal. This has,
on more than one occasion, led to debates, and delayed
decisions. The ASAQ Winthrop partnership, sanofi-aven-
tis and DNDi learned how to utilize their respective skills
to have the greatest possible impact. For instance, sanofi-
aventis provided its expertise in regulatory practices that
was critical in obtaining registration in countries and pre-
qualification by the WHO, and DNDi stressed the impor-
tance of providing instructions on packages that patients
with low literacy could understand. In addition, the two
organizations engaged complementary networks of con-
tact organizations and found that dialogue and actions
were often times easier and more fruitful when the part-
ners worked together rather than in isolation. Lastly, the
launch of ASAQ Winthrop in 2007 drew wide media
attention in both specialized and lay press. It is possible
that the global media exposure of the “$1 malaria treat-
ment” played a role in establishing the new reference
price for anti-malarials. Both organizations now under-
stand the importance of creative and innovative contracts
between public-private partnerships, and that joining
forces in a common development team can allow for pro-
gramme acceleration.
Both organizations decided to extend their successful
collaboration to ensure the deployment of ASAQ Win-
throp and monitor its long-term safety and efficacy.
This was formalized through the Risk Management
Plan, that is partly supported by Medicines for Malaria
Venture and by the royalties that sanofi-aventis pays to
DNDi from sales on the private markets. The lessons
learned from this experience could prove invaluable in
assessing future drugs’ efficacy and safety in the field.
Partnering with NMCPs to design and implement infor-
mational tools and techniques proved to be a very rich,
and ongoing, experience. Each country has its own prio-
rities in terms of information needs, and offering a vari-
ety of tools enables targeting specific audiences with
adapted tools and techniques. While tools intended for
health professionals usually only require minor country-
specific adaptations, those intended for communities
often require translation into local languages, as well as
the adaptation of pictures and drawings, so that local
populations effectively relate with the messages. Simi-
larly, collaboration with international purchasing agen-
cies requires adaptation to each organization’s
requirements and working habits, to establish long-term
effective relationships. Lastly, the importance of the con-
tribution of public and philanthropic funders at all
stages of the partnership cannot be overemphasized.
Overall, the result of the work performed by all part-
ners can be measured in the speed and extent with
which this new drug has been made available to African
patients. As of late 2010, ASAQ Winthrop is registered
in 30 sub-Saharan African countries and in India, and,
in the 3 years that have followed its prequalification by
the WHO, over 80 million treatments have been pur-
c h a s e db yg o v e r n m e n t so rN G O si n2 1c o u n t r i e s .T o
date, 10 clinical studies, sponsored by sanofi-aventis,
DNDi or academic teams, have been completed, invol-
ving 3432 patients and 9986 malaria episodes treated
with ASAQ Winthrop, in 16 African countries, as well
as in India and in Colombia (Table 2).
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Solutions to complex problems need the different and
complementary skills of various partners. The speed at
which ASAQ Winthrop was adopted by public health
officials and by patients in malaria-endemic countries
shows that this drug fitted a need. It also highlights the
efficacy of recent international efforts to bring malaria
medicines where they are needed, in particular more
efficient drugs procurement systems through better col-
laborations between endemic countries and funding
bodies. In this evolving and expanding partnership, all
involved have learned, and continue to learn valuable
skills in how public and private organizations can colla-
borate effectively. This success will hopefully serve to
inspire other organizations to consider the benefits of
public-private partnerships.
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